Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Expected to Post Quarterly Sales of $83.45 Million

Wall Street analysts expect Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get a rating) to announce sales of $83.45 million for the current fiscal quarter, Zacks Investment Research reports. Nine analysts made earnings estimates for Ultragenyx Pharmaceutical. The lowest sales estimate is $75.50 million and the highest is $96.49 million. Ultragenyx Pharmaceutical reported sales of $99.40 million in the same quarter last year, which would indicate a negative 16% year-over-year growth rate. The company is expected to release its next earnings report on Monday, January 1.

According to Zacks, analysts expect Ultranyx Pharmaceutical to report annual revenue of $378.21 million for the current fiscal year, with estimates ranging from $349.20 to $423.92 million. . For the next fiscal year, analysts expect the company to record sales of $472.89 million, with estimates ranging from $356.09 million to $591.20 million. Zacks sales calculations are an average average based on a survey of research analysts who follow Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ: RARE – Get a rating) last announced its quarterly results on Thursday, February 10. The biopharmaceutical company reported ($1.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.47). The company posted revenue of $83.39 million for the quarter, versus analyst estimates of $83.68 million. Ultragenyx Pharmaceutical posted a negative return on equity of 44.24% and a negative net margin of 129.20%. The company’s quarterly revenue was down 8.9% year over year. In the same quarter last year, the company posted ($1.34) earnings per share.

(A d)

What is the most productive stock you have ever owned? Dividends from these stocks have grown so rapidly over the years that they now earn us an average of 26%!

When you start getting paid 26% on your money, your financial troubles tend to evaporate.

Several research analysts have recently published reports on RARE stocks. JPMorgan Chase & Co. upgraded shares of Ultragenyx Pharmaceutical from a “neutral” rating to an “overweight” rating and set a price target of $132.00 for the company in a Friday, February 11 report. Zacks Investment Research upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating and set a price target of $75.00 for the company in a Tuesday, February 15 report. Credit Suisse Group upgraded Ultragenyx Pharmaceutical from a “neutral” rating to an “outperforming” rating and raised its price target for the company from $99.00 to $105.00 in a Wednesday, March 16 report. Morgan Stanley lowered its price target on Ultragenyx Pharmaceutical from $120.00 to $118.00 and set an “overweight” rating for the company in a Friday, Feb. 11 report. To finish, StockNews.com launched coverage on Ultragenyx Pharmaceutical in a Thursday, March 31 report. They issued a “hold” rating for the company. One analyst rated the security with a sell rating, four issued a hold rating and ten gave the security a buy rating. According to MarketBeat.com, the stock currently has an average buy rating and an average target price of $122.27.

In a similar vein, Executive Vice President Thomas Richard Kassberg sold 10,281 shares of Ultragenyx Pharmaceutical in a trade that took place on Friday, March 11. The shares were sold at an average price of $67.01, for a total value of $688,929.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via this link. Also, VPE Parschauer Karah Herdman sold 5,140 shares of Ultragenyx Pharmaceutical in a trade that took place on Monday, March 7. The shares were sold at an average price of $62.95, for a total transaction of $323,563.00. Disclosure of this sale can be found here. Last quarter, insiders sold 24,289 shares of the company valued at $1,602,749. Insiders of the company hold 6.70% of the shares of the company.

A number of large investors have recently changed their positions in the company. Nordea Investment Management AB increased its stake in Ultragenyx Pharmaceutical by 19.0% in the 1st quarter. Nordea Investment Management AB now owns 9,151 shares of the biopharmaceutical company valued at $660,000 after purchasing an additional 1,459 shares during the period. Privium Fund Management UK Ltd bought a new position in Ultragenyx Pharmaceutical in Q4, valued at $8,579,000. Norges Bank bought a new position in Ultragenyx Pharmaceutical in Q4, valued at $52,268,000. Barclays PLC increased its stake in shares of Ultragenyx Pharmaceutical by 396.9% during the 4th quarter. Barclays PLC now owns 23,430 shares in the biopharmaceutical company worth $1,970,000 after acquiring 18,715 additional shares in the last quarter. Finally, JustInvest LLC increased its stake in Ultragenyx Pharmaceutical shares by 113.2% during the 4th quarter. JustInvest LLC now owns 13,086 shares of the biopharmaceutical company worth $1,100,000 after acquiring 6,947 additional shares in the last quarter. 97.52% of the shares are held by hedge funds and other institutional investors.

NASDAQ:RARE shares opened at $85.40 on Friday. The company has a fifty-day moving average of $70.92 and a 200-day moving average of $76.77. The company has a market capitalization of $5.93 billion, a PE ratio of -12.73 and a beta of 1.68. Ultragenyx Pharmaceutical has a 52 week low of $61.21 and a 52 week high of $119.54.

Ultragenyx Pharmaceutical Company Profile (Get a rating)

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous used for the treatment of mucopolysaccharidosis VII.

See also

Get a Free Copy of Zacks’ Research Report on Ultragenyx Pharmaceutical (RARE)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings history and estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Ultragenyx Pharmaceutical right now?

Before you consider Ultragenyx Pharmaceutical, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Ultragenyx Pharmaceutical didn’t make the list.

Although Ultragenyx Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here